Nivolumab, as an immune checkpoint inhibitor (ICI), exerts its effect by enhancing host immune activity against tumor cells (7, 9), while Cetuximab acts as a molecular targeted therapy, directly interfering with tumor cell proliferation through inhibition of the epidermal growth factor receptor (EGFR) signaling cascade (10). Here, EGFR is linked to neoplasm.